Related Experiment Videos
Relation of clinical benefit to metabolic effects in lipid-lowering therapy
1Atherosclerosis Research Clinic, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
Studies of lipid-modifying therapy show that inhibition of cholesterol synthesis is required in at least 2 sites-in hepatic cells and in cells located in the walls of coronary arteries-if the progression of coronary atherosclerosis is to be decreased in patients with relatively normal levels of low-density lipoprotein (LDL) cholesterol. This is clinically important, because the majority of patients with coronary artery disease do not have severely elevated LDL cholesterol levels. Of the 2 angiographic trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors ("statins") in patients with coronary artery disease and average cholesterol levels, only the Lipoprotein and Atherosclerosis Study (LCAS) of fluvastatin reported slowed angiographic progression of coronary artery disease in these patients. The change in LDL cholesterol levels during treatment with fluvastatin did not predict the extent of change in coronary atherosclerosis or incidence of clinical cardiac events. Apparently, the metabolic effects of treatment with fluvastatin were more important than the extent to which blood cholesterol levels were lowered. The clinical benefits of treatment with statins should be directly compared in randomized controlled clinical trials among patients with average cholesterol levels.
Insights
Inhibition of cholesterol synthesis in both liver and artery cells is key to reducing coronary atherosclerosis progression, particularly in patients with normal LDL cholesterol. Fluvastatin
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Coronary atherosclerosis progression impacts many patients, often with normal LDL cholesterol levels.
- Lipid-modifying therapies require cholesterol synthesis inhibition in both hepatic and arterial cells.
- Statins are a class of lipid-modifying drugs.
Purpose of the Study:
- To investigate the efficacy of fluvastatin in slowing coronary atherosclerosis progression in patients with average cholesterol levels.
- To determine if changes in LDL cholesterol levels correlate with slowed angiographic progression or reduced cardiac events.
- To highlight the importance of metabolic effects over LDL reduction in statin therapy.
Main Methods:
- Analysis of angiographic trials involving 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins).
- Focus on the Lipoprotein and Atherosclerosis Study (LCAS) using fluvastatin.
- Evaluation of coronary atherosclerosis progression and clinical cardiac events in patients with average cholesterol.
Main Results:
- Fluvastatin treatment slowed angiographic progression of coronary artery disease in patients with average cholesterol levels.
- Changes in LDL cholesterol levels did not predict the extent of coronary atherosclerosis change or clinical cardiac events.
- Metabolic effects of fluvastatin appeared more significant than LDL cholesterol reduction.
Conclusions:
- Cholesterol synthesis inhibition in both liver and artery cells is crucial for decreasing coronary atherosclerosis.
- Statin therapy's benefits may stem from metabolic effects beyond LDL cholesterol reduction.
- Direct comparative clinical trials are needed to assess statin benefits in patients with average cholesterol levels.